Eisai, Astellas Experience Delays In Seeking U.S. Drug Approvals
This article was originally published in PharmAsia News
Eisai and Astellas Pharma separately announced delays in seeking U.S. approval for new drugs, Eisai for more than a year. Eisai said the decision to put off applying for its E7389 (eribulin mesylate) cancer drug would affect the company's long-term business goals. But President Haruo Naito added the company expects to garner more sales at the beginning of its eventual marketing effort as a result. Astellas said it would delay filing for a new formulation of its Prograf (tacrolimus) as a liver transplant immunosuppressant by three months because the U.S. FDA said it needed that time to review the application. (Click here for more
You may also be interested in...
The US FDA’s decision to ask on device adverse event reports whether the device involved had been serviced by a third party could help the agency as well as device makers, says Ricki Chase, compliance practice director at Lachman Consultant Services.
The FDA has almost 30 decision dates coming up before New Year’s Eve, including nearly a dozen novel agents.
Complaint lists host of problems with implementation of the rule that allows states to sponsor programs to import certain prescription drugs from Canada; at least six states have enacted legislation to sponsor these programs.